car-t gives sustained disease control in r/r adult dlbcl: updated juliet analysis
Published 5 years ago • 83 plays • Length 4:27Download video MP4
Download video MP3
Similar videos
-
2:25
juliet: crs and neurotoxicity in dlbcl
-
3:52
updates on the use of car-t therapy for the treatment of dlbcl in the second-line setting
-
0:32
enhancing outcomes of patients with dlbcl treated with car t-cell therapy
-
2:01
advances in cd22/cd19 car-t sequential therapy
-
5:09
the evolving role of nurses in the field of car-t
-
8:36
the end of cancer? car t-cell therapy & the biology revolution
-
5:04
dlbcl and car t cell therapy - kim's lymphoma story
-
9:11
chimeric antigen receptor car technique - creative biolabs (original version)
-
3:08
current car-t treatments for t-all and next steps
-
2:38
car t-cells improve response and cr rates in r/r dlbcl
-
3:56
considerations and challenges of integrating car-t and transplantation in b-all
-
3:06
repeat infusions of cd19 car-t
-
2:06
managing and treating crs, neurological toxicity and cytopenias associated with car-t therapy
-
2:02
carpall and amelia: ongoing data for car-t in all
-
2:50
state of the art in car-t
-
1:39
exploring the applications of car-ts beyond hematology and oncology
-
2:26
clinical data for cd19-directed car t-cell products in all
-
1:43
management of car-t related side effects
-
1:33
patient selection for car-t in all
-
3:27
using ai to predict patient response to car-t cell therapy: analysis of the juliet trial
-
2:30
car-t as a new standard of care in lymphoma
-
2:08
challenges with car-t therapy in aml & insights into if-better-gated car-t cells